Janssen focuses cardiometabolic R&D on prevention, cure and interception

With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia. Speaking at Biotech Showcase, List explained to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how he is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: James F. List – Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), Janssen